The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 140.0 million in the second quarter of 2026 (Q2 2025: NOK 135.6 million), and an adjusted EBITDA of NOK 27.2 million (Q2 2025: ...
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder ...
Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.
Access to a non-invasive test shouldn't depend on where someone lives or which local service has managed to adopt it first, ...
Cardiac masses in neonates are rare and most often benign tumours such as rhabdomyomas, fibromas or teratomas. Rarely, ...
(UroToday.com) The 2026 AUA annual meeting featured a health services research session and a presentation by Dr. Ali Nasrallah discussing costs of care and oncologic outcomes associated with blue ...
Cystoscopy is a cornerstone of urological diagnosis and surveillance, yet it remains associated with patient discomfort and procedural anxiety. Contemporary pain management encompasses pharmacological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results